AstraZeneca: Farxiga Approved in the US for the Treatment of Pediatric Type-2 Diabetes
June 13, 2024
June 13, 2024
WILMINGTON, Delaware, June 13 -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 12, 2024:
AstraZeneca's FARXIGA(R) (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older.1 The FDA approval was based on positive results from the pediatric T2NOW Phase III trial.2 FARXIGA was previously approved in the US in adults with T2D as . . .
AstraZeneca's FARXIGA(R) (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older.1 The FDA approval was based on positive results from the pediatric T2NOW Phase III trial.2 FARXIGA was previously approved in the US in adults with T2D as . . .